Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology

Behnood Bikdeli, Thomas McAndrew, Aaron Crowley, Shmuel Chen, Ghazaleh Mehdipoor, Björn Redfors, Yangbo Liu, Zixuan Zhang, Mengdan Liu, Yiran Zhang, Dominic P. Francese, David Erlinge, Stefan K. James, Yaling Han, Yi Li, Adnan Kastrati, Stefanie Schüpke, Rod H. Stables, Adeel Shahzad, Philippe Gabriel StegPatrick Goldstein, Enrico Frigoli, Roxana Mehran, Marco Valgimigli, Gregg W. Stone

Forskningsoutput: TidskriftsbidragLetterPeer review

9 Citeringar (SciVal)


BACKGROUND:  Individual randomized controlled trials (RCTs) of periprocedural anticoagulation with bivalirudin versus heparin during percutaneous coronary intervention (PCI) have reported conflicting results. Study-level meta-analyses lack granularity to adjust for confounders, explore heterogeneity, or identify subgroups that may particularly benefit or be harmed. OBJECTIVE:  To overcome these limitations, we sought to develop an individual patient-data pooled database of RCTs comparing bivalirudin versus heparin. METHODS:  We conducted a systematic review to identify RCTs in which ≥1,000 patients with acute myocardial infarction (AMI) undergoing PCI were randomized to bivalirudin versus heparin. RESULTS:  From 738 identified studies, 8 RCTs met the prespecified criteria. The principal investigators of each study agreed to provide patient-level data. The data were pooled and checked for accuracy against trial publications, with discrepancies addressed by consulting with the trialists. Consensus-based definitions were created to resolve differing antithrombotic, procedural, and outcome definitions. The project required 3.5 years to complete, and the final database includes 27,409 patients (13,346 randomized to bivalirudin and 14,063 randomized to heparin). CONCLUSION:  We have created a large individual patient database of bivalirudin versus heparin RCTs in patients with AMI undergoing PCI. This endeavor may help identify the optimal periprocedural anticoagulation regimen for patient groups with different relative risks of adverse ischemic versus bleeding events, including those with ST-segment and non-ST-segment elevation MI, radial versus femoral access, use of a prolonged bivalirudin infusion or glycoprotein inhibitors, and others. Adherence to standardized techniques and rigorous validation processes should increase confidence in the accuracy and robustness of the results.

Sidor (från-till)348-362
Antal sidor15
TidskriftThrombosis and Haemostasis
StatusPublished - 2020 feb.

Ämnesklassifikation (UKÄ)

  • Kardiologi


Utforska forskningsämnen för ”Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här